Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Conmed (CNMD) EPS (Weighted Average and Diluted) (2016 - 2025)

Conmed (CNMD) has disclosed EPS (Weighted Average and Diluted) for 11 consecutive years, with $0.81 as the latest value for Q4 2020.

  • For the quarter ending Q4 2020, EPS (Weighted Average and Diluted) rose 65.31% year-over-year to $0.81, compared with a TTM value of $0.28 through Dec 2020, down 70.53%, and an annual FY2025 reading of $1.51, down 64.47% over the prior year.
  • EPS (Weighted Average and Diluted) was $0.81 for Q4 2020 at Conmed, up from $0.23 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $1.65 in Q4 2017 and bottomed at -$0.96 in Q2 2020.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.26, with a median of $0.23 recorded in 2019.
  • The sharpest move saw EPS (Weighted Average and Diluted) skyrocketed 587.5% in 2017, then plummeted 605.26% in 2020.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.24 in 2016, then surged by 587.5% to $1.65 in 2017, then plummeted by 67.27% to $0.54 in 2018, then dropped by 9.26% to $0.49 in 2019, then soared by 65.31% to $0.81 in 2020.
  • Business Quant data shows EPS (Weighted Average and Diluted) for CNMD at $0.81 in Q4 2020, $0.23 in Q3 2020, and -$0.96 in Q2 2020.